An open-source data set of anti-VEGF therapy in diabetic macular oedema patients over 4 years and their visual acuity outcomes.
Christoph KernDun Jack FuJosef HuemerLivia FaesSiegfried K WagnerKarsten KortuemPraveen J PatelRanjan RajendramKonstantinos BalaskasRobin HamiltonDawn A SimPearse Andrew KeanePublished in: Eye (London, England) (2020)
To date, this is the largest single centre cohort study and over the longest observation period reporting on real-life outcomes of anti-VEGF in DMO. We have made an anonymised version of our data set available on an open-source data repository as a resource for clinical researchers globally.
Keyphrases
- electronic health record
- end stage renal disease
- big data
- vascular endothelial growth factor
- ejection fraction
- endothelial cells
- newly diagnosed
- chronic kidney disease
- type diabetes
- prognostic factors
- optical coherence tomography
- adverse drug
- metabolic syndrome
- adipose tissue
- mesenchymal stem cells
- diabetic retinopathy
- skeletal muscle
- deep learning
- psychometric properties
- drug induced